Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation-Reference-Cited by-同舟云学术

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation

Published:2011-04 Issue:4 Volume:22 Page:939-946
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Giralt S.A.,Mangan K.F.,Maziarz R.T.,Bubalo J.S.,Beveridge R.,Hurd D.D.,Mendoza F.L.,Rubenstein E.B.,DeGroot T.J.,Schuster M.W.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/4/939/570132/mdq457.pdf

Reference35 articles.

1. Multiple myeloma;Kyle;Blood,2008

2. Multiple myeloma cancer stem cells;Huff;J Clin Oncol,2008

3. Stem cell transplantation for multiple myeloma;Gasparetto;Cancer Control,2004

4. Ondansetron—a new safe and effective antiemetic in patients receiving high-dose melphalan;Viner;Cancer Chemother Pharmacol,1990

5. Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support;Ballen;Bone Marrow Transplant,2001

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review;European Journal of Haematology;2024-07-29

2. Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation;Frontiers in Oncology;2023-11-21

3. Ocular Administration of Palonosetron in the Prevention of Cisplatin-Induced Nausea and Vomiting;Journal of Pharmacology and Experimental Therapeutics;2023-01-12

4. Antiemetic Therapy;Holland‐Frei Cancer Medicine;2022-10-21

5. Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation;Clinical Hematology International;2022-07-11